📊TATA ELXSI LIMITED (#TATAELXSI)

🏷Market Cap: 52,550 Cr

🏷One of the World’s leading provider of design and technology services across industries including Automotive, Broadcast & communications and Healthcare

💥Business Analysis

A Thread 🧵

🌁BUSINESS

🏷Part of prestigious TATA Group

🏷Established in 1989, A forward looking IT business

🏷Company earns revenue primarily from providing information technology, engineering design, systems integration & support services, sale of licenses and maintenance of equipment
🌁The company operates in 2 segments

1. Software Development & Services

It is further sub divided into EPD and IDV.

🏷Embedded Product Design (EPD)
🏷Industrial Design & Visualisation (IDV) division

2. System Integration & Support (SIS)
🌁MANAGEMENT

🏷Manoj Raghavan (MD & CEO) : 22 Years of experience (2.42 Yrs tenure)

🏷CEO compensation ($USD 578.96K) is below average for companies of similar size

🏷CEO compensation has increased by more than 20% in the past year
🌁SHAREHOLDING PATTERN

🏷Change in promoter holding (Vs last quarter): -0.21%

🏷Change in FII holding (Vs last quarter): -0.78%

🏷Change in DII holding (Vs last quarter): +0.59%

🏷Change in public holding (Vs last quarter): +0.41%
🌁CONTRIBUTION TO DIFFERENT INDUSTRIES

Company is mainly working for below industries

1. Automotive
2. Broadcast & Communications
3. Healthcare
🌁WELL DIVERSIFIED REVENUE MIX (Q3 FY22)

🏷Geography

Americas: 42.3%, Europe: 32.8%, India: 16.7%, RoW: 8.2%

🏷Segment

Embedded Product Design: 88.9%
Industrial Design & Visualisation: 8.9%
System Integration & Support: 2.2%
🌁Client concentration & Employee Metrics

🏷People addition in Q3 FY22: 414

🏷Employee utilisation rate ~83%

❌Attrition Rate: 18.2% (LTM)
🌁QUARTERLY RESULTS (Q3 FY22)

🏷Sales Growth: 33.2% YoY - Good YoY Sales Growth

🏷Profit: 43.5% YoY - Good YoY Profit Growth

🏷Consistent growth in margins

🏷Strong order book and a healthy deal pipeline

🏷The company is debt free since long
🌁FINANCIALS (5 Year CAGR)

🏷Sales Growth: 11.2%

🏷EBITDA Growth: 16.2%

🏷PAT Growth: 18.9%

🏷ROCE: 42.5% (FY21)

🏷ROE: 30.2%

Working capital days of the company in FY21 stood at ~65 days

Free cash flow per share increased to 62 Rs in FY 21

Overall, Numbers look good.
🌁STRENGTHS

🏷Diversified geographical presence
🏷Established market position
🏷Healthy financial operations
🏷Major contributor to the transformation to Electric Vehicle
🏷Company consistently making profits
🏷Debt free since long
🏷Brokers upgraded recommendation
🌁WEAKNESS

🏷Trading at Premium Valuation
🏷Promoter and FII reduced the holding in Q3 FY22
🏷Good competition from KPIT and LTTS
🏷~88% revenue from one segment, Embedded Product Design
🌁VALUATION

🏷Price to Earnings (PE): 104 (Above it’s median PE 27.6)
🏷Price to book value: 40.7
🏷PEG Ratio: 5.53

Although there is bright growth prospect, at current levels stock is trading at premium valuation (Overvalued).
🌁CHART (Weekly Timeframe)

More from Tataelxsi

You May Also Like

Moderna CEO Stephane Bancel was previously CEO of bioMerieux in France from 07-10.

Alain Merieux, who owns bioMerieux, was instrumental in the creation of the Wuhan Institute of Virology P4 Lab.

The same people who helped create the virus, also helped to create the vaccines...


Moderna partnered with French Pasteur Institute in 2015 to develop mRNA vaccine technology.

Pasteur Institute partnered with the Wuhan P4 Laboratory in 2017 along with the Merieux Foundation to study emerging viruses...
https://t.co/yFsHwrNYaK
https://t.co/9M5lydBKhM


Nobel prize winning scientist Luc Montagnier asserts that Sars-Cov-2 is man-made and originated from the Wuhan Institute of Virology.

Montagnier did extensive work with the Pasteur Institute in France which was partnered with the Wuhan P4.

Merieux Foundation & the Chinese government have worked together since 1965, and partnered to study emerging pathogens in Africa in 2015.

Their research included "PATHOGENS CARRIED BY BATS" that provoke respiratory diseases.

🚨🚨🚨
https://t.co/gVwpT0ssqI